A Novel Ruthenium(II) Complex With Lapachol Induces G2/M Phase Arrest Through Aurora-B Kinase Down-Regulation and ROS-Mediated Apoptosis in Human Prostate Adenocarcinoma Cells.
Autor: | De Grandis RA; School of Pharmaceutical Sciences, São Paulo State University, Araraquara, Brazil.; School of Medicine, University of Araraquara, Araraquara, Brazil., Oliveira KM; Department of Chemistry, Federal University of São Carlos, São Carlos, Brazil., Guedes APM; Department of Chemistry, Federal University of São Carlos, São Carlos, Brazil., Dos Santos PWS; School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil., Aissa AF; Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago College of Medicine, Chicago, IL, United States., Batista AA; Department of Chemistry, Federal University of São Carlos, São Carlos, Brazil., Pavan FR; School of Pharmaceutical Sciences, São Paulo State University, Araraquara, Brazil. |
---|---|
Jazyk: | angličtina |
Zdroj: | Frontiers in oncology [Front Oncol] 2021 Jun 24; Vol. 11, pp. 682968. Date of Electronic Publication: 2021 Jun 24 (Print Publication: 2021). |
DOI: | 10.3389/fonc.2021.682968 |
Abstrakt: | Lapachol is a well-studied natural product that has been receiving great interest due to its anticancer properties that target oxidative stress. In the present work, two novel lapachol-containing ruthenium(II) complexes [Ru(Lap)(dppm)(bipy)]PF Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 De Grandis, Oliveira, Guedes, dos Santos, Aissa, Batista and Pavan.) |
Databáze: | MEDLINE |
Externí odkaz: |